RS62440B1 - Derivati fenila kao modulatori receptora pge2 - Google Patents
Derivati fenila kao modulatori receptora pge2Info
- Publication number
- RS62440B1 RS62440B1 RS20211256A RSP20211256A RS62440B1 RS 62440 B1 RS62440 B1 RS 62440B1 RS 20211256 A RS20211256 A RS 20211256A RS P20211256 A RSP20211256 A RS P20211256A RS 62440 B1 RS62440 B1 RS 62440B1
- Authority
- RS
- Serbia
- Prior art keywords
- receptor modulators
- phenyl derivatives
- pge2 receptor
- pge2
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2017062031 | 2017-05-18 | ||
EP18725222.6A EP3625222B1 (en) | 2017-05-18 | 2018-05-17 | Phenyl derivatives as pge2 receptor modulators |
PCT/EP2018/062862 WO2018210994A1 (en) | 2017-05-18 | 2018-05-17 | Phenyl derivatives as pge2 receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
RS62440B1 true RS62440B1 (sr) | 2021-11-30 |
Family
ID=62186480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20211256A RS62440B1 (sr) | 2017-05-18 | 2018-05-17 | Derivati fenila kao modulatori receptora pge2 |
Country Status (32)
Country | Link |
---|---|
US (1) | US11712438B2 (sr) |
EP (1) | EP3625222B1 (sr) |
JP (1) | JP7159214B2 (sr) |
KR (1) | KR102632028B1 (sr) |
CN (1) | CN110612296A (sr) |
AR (1) | AR111941A1 (sr) |
AU (1) | AU2018269666B2 (sr) |
BR (1) | BR112019024109A2 (sr) |
CA (1) | CA3060597A1 (sr) |
CL (1) | CL2019003275A1 (sr) |
CO (1) | CO2019010578A2 (sr) |
CR (1) | CR20190559A (sr) |
CY (1) | CY1124608T1 (sr) |
DK (1) | DK3625222T3 (sr) |
EA (1) | EA201992676A1 (sr) |
ES (1) | ES2893452T3 (sr) |
HR (1) | HRP20211533T1 (sr) |
HU (1) | HUE056080T2 (sr) |
IL (1) | IL270623B2 (sr) |
LT (1) | LT3625222T (sr) |
MA (1) | MA49126B1 (sr) |
MX (1) | MX2019013718A (sr) |
PE (1) | PE20191814A1 (sr) |
PH (1) | PH12019502563A1 (sr) |
PL (1) | PL3625222T3 (sr) |
PT (1) | PT3625222T (sr) |
RS (1) | RS62440B1 (sr) |
SG (1) | SG11201908729UA (sr) |
SI (1) | SI3625222T1 (sr) |
TW (1) | TWI765041B (sr) |
UA (1) | UA125123C2 (sr) |
WO (1) | WO2018210994A1 (sr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
TW201900178A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之嘧啶衍生物 |
CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
CN111819193A (zh) | 2018-01-05 | 2020-10-23 | 西奈山伊坎医学院 | 增加胰腺β细胞增殖的方法、治疗方法以及组合物 |
US11866427B2 (en) | 2018-03-20 | 2024-01-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
US20220064146A1 (en) * | 2018-12-31 | 2022-03-03 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
TW202228674A (zh) | 2020-11-13 | 2022-08-01 | 日商小野藥品工業股份有限公司 | 藉由併用ep4拮抗藥與免疫檢查點抑制物質而進行之癌症治療 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
CA2402099C (en) | 2000-03-24 | 2011-04-26 | Pharmagene Laboratories Ltd. | Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment |
HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
WO2003086390A1 (en) | 2002-04-12 | 2003-10-23 | Pfizer Japan Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
AU2003216581A1 (en) | 2002-04-12 | 2003-10-27 | Pfizer Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
AU2003233297A1 (en) | 2002-05-23 | 2003-12-12 | Theratechnologies Inc | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
WO2004067524A1 (en) | 2003-01-29 | 2004-08-12 | Pharmagene Laboratories Limited | Ep4 receptor antagonists |
TW200509938A (en) | 2003-08-26 | 2005-03-16 | Teijin Pharma Ltd | Pyrrolopyrimidine thion derivatives |
BRPI0414130B8 (pt) | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem. |
EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
WO2005105732A1 (en) | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Substituted methyl aryl or heteroaryl amide compounds |
BRPI0510598A (pt) | 2004-05-04 | 2007-11-20 | Pfizer | compostos de amida de aril ou heteroaril substituìdos |
HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
EP1885722B1 (en) | 2005-05-19 | 2011-11-16 | Merck Canada Inc. | Quinoline derivatives as ep4 antagonists |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
DOP2007000068A (es) | 2006-04-12 | 2007-10-31 | Sanofi Aventis Us Llc | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2 |
JP5244091B2 (ja) | 2006-04-24 | 2013-07-24 | メルク カナダ インコーポレイテッド | Ep4受容体アンタゴニストとしてのインドールアミド誘導体 |
CA2654811A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
US7989458B2 (en) | 2006-07-14 | 2011-08-02 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
CA2660133C (en) | 2006-08-11 | 2015-10-27 | Merck Frosst Canada Ltd. | Thiophenecarboxamide derivatives as ep4 receptor ligands |
WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
CN101622230B (zh) | 2007-02-26 | 2012-08-22 | 默克弗罗斯特加拿大有限公司 | 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物 |
JP2010522218A (ja) | 2007-03-26 | 2010-07-01 | メルク フロスト カナダ リミテツド | Ep4受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体 |
WO2008123207A1 (ja) | 2007-03-26 | 2008-10-16 | Astellas Pharma Inc. | オルニチン誘導体 |
EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
WO2009005076A1 (ja) | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
JP5681855B2 (ja) | 2007-10-12 | 2015-03-11 | アストラゼネカ エービー | プロテインキナーゼの阻害剤 |
US8598202B2 (en) | 2008-02-19 | 2013-12-03 | Janssen Pharmaceutica Nv | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
EP2565191B1 (en) | 2008-05-14 | 2014-10-08 | Astellas Pharma Inc. | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy |
US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
JP5536773B2 (ja) | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体 |
GB2474813B (en) | 2008-09-19 | 2014-05-28 | Biotechnology Res Corp Ltd | Triterpenoid compounds and methods of use thereof |
MX2011003166A (es) | 2008-09-25 | 2011-04-27 | Merck Frosst Canada Ltd | Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4. |
WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
EP2504008A1 (en) | 2009-11-23 | 2012-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
AU2011254550B2 (en) | 2010-05-21 | 2013-11-07 | Noviga Research Ab | Novel pyrimidine derivatives |
RS55566B1 (sr) | 2010-09-21 | 2017-05-31 | Eisai R&D Man Co Ltd | Farmaceutska kompozicija |
NZ609887A (en) | 2010-09-29 | 2015-01-30 | Nb Health Lab Co Ltd | Antibody against human prostaglandin e2 receptor ep4 |
WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
MX2013005535A (es) | 2010-11-17 | 2013-07-03 | Novartis Ag | Compuesto de 3- (amino-aril) -piridina. |
CA2820109C (en) | 2010-12-10 | 2018-01-09 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
EP2702043A1 (en) | 2011-04-29 | 2014-03-05 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
CA2839956A1 (en) | 2011-06-20 | 2012-12-27 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
CN103702980B (zh) | 2011-07-04 | 2016-10-05 | 罗达制药生物技术有限责任公司 | 环胺衍生物作为ep4受体拮抗剂 |
EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
US20150004175A1 (en) | 2011-12-13 | 2015-01-01 | Yale University | Compositions and Methods for Reducing CTL Exhaustion |
NZ700928A (en) * | 2012-04-24 | 2017-06-30 | Vertex Pharma | Dna-pk inhibitors |
TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
JO3296B1 (ar) | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
EP2925744B1 (en) | 2012-11-27 | 2020-12-30 | Thomas Helledays Stiftelse För Medicinsk Forskning | Pyrimidine-2,4-diamine derivatives for treatment of cancer |
UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫-1h-異喹啉化合物 |
UA118562C2 (uk) | 2013-05-30 | 2019-02-11 | Ідорсія Фармасьютікалз Лтд | Модулятори рецептора cxcr7 |
CA2914997C (en) | 2013-06-12 | 2021-07-20 | Kaken Pharmaceutical Co., Ltd. | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient |
CA2923184A1 (en) | 2013-09-04 | 2015-03-12 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
JP6521977B2 (ja) | 2013-09-06 | 2019-05-29 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 免疫調節剤としての1,2,4−オキサジアゾール誘導体 |
WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
HUE041877T2 (hu) | 2013-10-17 | 2019-06-28 | Vertex Pharma | (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként |
CA2927392C (en) * | 2013-10-17 | 2021-11-09 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
HUE035698T2 (en) | 2013-12-17 | 2018-05-28 | Lilly Co Eli | Phenoxyethyl ring amine derivatives and their activity as EP4 receptor modulator |
PT3083554T (pt) | 2013-12-17 | 2019-06-11 | Lilly Co Eli | Compostos de ácido dimetilbenzóico |
TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ep4配體之新穎苯并咪唑衍生物 |
TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
EP3137074B1 (en) | 2014-04-29 | 2020-08-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
KR102535283B1 (ko) | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
CA2948601A1 (en) | 2014-06-04 | 2015-12-10 | Thomas Helledays Stiftelse For Medicinsk Forskning | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions |
EA034691B1 (ru) | 2014-06-19 | 2020-03-06 | Ариад Фармасьютикалз, Инк. | Гетероарильные соединения для ингибирования киназ |
WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
KR102376248B1 (ko) | 2015-01-09 | 2022-03-21 | 오노 야꾸힝 고교 가부시키가이샤 | 삼환성 스피로 화합물 |
EP3325490B1 (en) | 2015-07-23 | 2019-12-18 | Takeda Pharmaceutical Company Limited | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists |
WO2017066633A1 (en) | 2015-10-16 | 2017-04-20 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
CA3030783A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
SI3625224T1 (sl) | 2017-05-18 | 2021-11-30 | Idorsia Pharmaceuticals Ltd | N-substituirani indolni derivati |
TW201900178A (zh) | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 作為pge2受體調節劑之嘧啶衍生物 |
CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
-
2018
- 2018-05-17 HU HUE18725222A patent/HUE056080T2/hu unknown
- 2018-05-17 HR HRP20211533TT patent/HRP20211533T1/hr unknown
- 2018-05-17 WO PCT/EP2018/062862 patent/WO2018210994A1/en unknown
- 2018-05-17 MA MA49126A patent/MA49126B1/fr unknown
- 2018-05-17 LT LTEPPCT/EP2018/062862T patent/LT3625222T/lt unknown
- 2018-05-17 UA UAA201911975A patent/UA125123C2/uk unknown
- 2018-05-17 CR CR20190559A patent/CR20190559A/es unknown
- 2018-05-17 TW TW107116759A patent/TWI765041B/zh not_active IP Right Cessation
- 2018-05-17 CN CN201880031321.4A patent/CN110612296A/zh active Pending
- 2018-05-17 DK DK18725222.6T patent/DK3625222T3/da active
- 2018-05-17 KR KR1020197037298A patent/KR102632028B1/ko active IP Right Grant
- 2018-05-17 PT PT18725222T patent/PT3625222T/pt unknown
- 2018-05-17 CA CA3060597A patent/CA3060597A1/en active Pending
- 2018-05-17 JP JP2019563491A patent/JP7159214B2/ja active Active
- 2018-05-17 RS RS20211256A patent/RS62440B1/sr unknown
- 2018-05-17 SG SG11201908729U patent/SG11201908729UA/en unknown
- 2018-05-17 AR ARP180101315A patent/AR111941A1/es unknown
- 2018-05-17 AU AU2018269666A patent/AU2018269666B2/en not_active Ceased
- 2018-05-17 IL IL270623A patent/IL270623B2/en unknown
- 2018-05-17 BR BR112019024109-4A patent/BR112019024109A2/pt not_active IP Right Cessation
- 2018-05-17 SI SI201830422T patent/SI3625222T1/sl unknown
- 2018-05-17 MX MX2019013718A patent/MX2019013718A/es unknown
- 2018-05-17 EA EA201992676A patent/EA201992676A1/ru unknown
- 2018-05-17 PL PL18725222T patent/PL3625222T3/pl unknown
- 2018-05-17 EP EP18725222.6A patent/EP3625222B1/en active Active
- 2018-05-17 ES ES18725222T patent/ES2893452T3/es active Active
- 2018-05-17 US US16/614,594 patent/US11712438B2/en active Active
- 2018-05-17 PE PE2019002396A patent/PE20191814A1/es unknown
-
2019
- 2019-09-27 CO CONC2019/0010578A patent/CO2019010578A2/es unknown
- 2019-11-15 PH PH12019502563A patent/PH12019502563A1/en unknown
- 2019-11-15 CL CL2019003275A patent/CL2019003275A1/es unknown
-
2021
- 2021-10-19 CY CY20211100906T patent/CY1124608T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201906104B (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
IL259424B (en) | Nitrogen-substituted indole derivatives as pge2 receptor modulators | |
MA43382A (fr) | Modulateurs des récepteurs des chimiokines | |
LT3625222T (lt) | Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai | |
IL270620A (en) | Pyrimidine history as PGE2 receptor modulators | |
HRP20190024T1 (hr) | Derivati hidroksialkil-piperazina kao modulatori receptora cxcr3 | |
EP3186225A4 (en) | Cannabinoid type 1 receptor modulators | |
GB201716468D0 (en) | Modulators | |
DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
HK1257091A1 (zh) | 茚烷衍生物作為mglur7調節劑 | |
HK1254769A1 (zh) | 包含s1p受體調節劑的組合物 | |
GB2563095B (en) | Modulators | |
GB201702926D0 (en) | Modulators | |
GB201616065D0 (en) | Receptor modulator compounds | |
GB201616072D0 (en) | Receptor modulator compounds | |
GB201616071D0 (en) | Receptor modulator compounds | |
GB201512714D0 (en) | Receptor modulator compounds |